Next Phase Newsletter

A Swedish venture capital fund that invests in life science companies with a focus on therapeutics is currently seeking new opportunities. The firm has raised six funds to date, with the most recent fund size of €110M (2011 vintage). The firm can allocate up to €10-15M per company and typically provides equity as well as debt financing. The firm generally acts as the lead or co-lead investor and is open to invest in syndicates. Currently, the firm seeks to invest in companies that are based in the European Union or US company that is open to establish an EU entity.

The firm is currently seeking to invest in early to mid stage biotech therapeutics and pharmaceuticals. The firm is also interested in exceptional medical devices with a therapeutic application that is close to market or has generated some sales. The firm is opportunistic across the therapeutic subsectors but prefers products that target niche indications.  Currently, the firm is more interested in oncology and orphan indications.  The firm looks for products with proofs of concept in Phase I and II.

The firm requests a board seat in each portfolio company. The firm seeks a strong and experienced management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of an integrated health care consortium based in the United States manages ~ $410 million in assets and is making the investments out of a ~$150 million dollar fund. The firm can invest as little as $5 million but tends to allocate $7-$10 million initially, and $10-$15 million over the lifetime of an investment. The firm only invests in preferred equity rounds, is comfortable leading life sciences deals, particularly in healthcare IT. The firm only invests in US-based and incorporated companies. The firm is involved in approximately 4-5 new investments each year.

The firm is currently looking for companies in healthcare IT, healthcare services, diagnostics, medical devices, and drug delivery. Companies that are able to benefit the firm’s existing healthcare members are of particular interest. The firm is indication agnostic, however, and is not interested in investing into companies working with novel compounds or therapeutics. The firm is looking for mid to later stage companies for investment.

The firm looks to invest in companies that have already received institutional funding from highly qualified investors where the investor syndicate has majority stake in the company. The firm will consider companies that are both pre and post revenue, but is primarily interested in companies with early (single digit millions) commercial traction. The firm started making investments out of its fourth fund earlier this year.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A life science dedicated PE fund of a Taiwanese company engaged in leasing, finance, and investment businesses is currently seeking new opportunities. The fund prefers to invest in early stage companies but is also interested in growth-expansion stage companies. The fund can invest up to USD 30 million or more per company.  The fund will focus on companies founded and operated in the Greater China region (60% of fund allocation). The fund is also interested in opportunities from Europe (especially in Switzerland, Germany, and the UK) as well as from the US.

The fund seeks to invest in biopharmaceuticals and medical technologies. In biopharma, the fund focuses on novel drugs, drugs with new indication/dosage form, biosimilar, and API for cancer drug. The fund looks for proprietary drug discovery or development technologies that are able to build a multi-product pipeline and products that address large unmet medical needs. For medical technologies, the firm focuses on molecular IVD test/next-generation sequencing, monitor & diagnostics system, invasive devices, cosmetics/plastic surgery, ICT medical device, and combination products with Greater China market potential. The firm looks for new and innovative technologies that can increase performance, lower cost or open up new business models.

The fund prefers to invest in early stage companies and generally acquires a minority stake in the company. However, the fund does not rule out the possibilities of acquiring a controlling stake if the strategic value exists.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the southwestern United States manages 2 funds for a combined total of $270 million in assets under management. The firm generally invests between $2-$6 million of equity capital per round and up to $10-$15 million over the life of the investment. The firm plans to invest in 2-5 companies over the next 6-9 months and will consider firms located throughout the United States.

The firm is currently looking for companies developing Medical Devices, Therapeutics, Diagnostics and Healthcare IT products. For medical devices and therapeutics the firm is open to the full spectrum of subsector and indication and will consider companies developing orphan indications. The firm is interested in seed and venture stage companies, generally looking to invest in companies with a lead asset in pre-clinical trials. Only in certain cases of reformulation and repurposing would the firm consider investment into a company with a product in clinical trials. The firm is also willing to consider companies targeting orphan indications. In the Healthcare IT space the firm has stated interest in areas of clinical sequencing and diagnostic platforms but will also consider other companies that fall into the Healthcare IT space as well with the exception of traditional EMR companies. The firm is also considering investment into mobile health companies developing consumer facing apps.

As such an early stage investor, the firm invests almost exclusively in pre-revenue companies. The firm also looks for experienced management teams and generally takes a seat on the company’s board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office/venture capital firm based in New York firm manages an evergreen fund that seeks to make seed, venture, and growth equity investments in early to mid-stage medical device companies, but will also consider secured debt to help revenue generating companies with short term cash flow issues. The firm will also consider pre-seed investments. The firm can allocate anywhere from $1M to $10M per company, but generally allocates around $8M. The firm typically does 3 rounds of financing with an initial investment of around $3M. The firm is geographically agnostic, but highly prefers to invest in companies that are based in the US. The firm seeks to make about 3-4 allocations in the next 6-9 months.

The firm is currently looking for medical device companies with a strong emphasis on products with a 510(k) regulatory pathway. In terms of subsectors, the firm is looking for products specifically in the areas of interventional radiology and cardiology, spine/orthopedics and minimally invasive surgery. The firm is generally opportunistic in terms of indication.

The firm is looking to invest in companies with a management team with a track record of success in the healthcare industry. However, the firm is generally flexible and does not require a full management team. The firm can assemble the management team over the course of the investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Allocation Information:

A leading medical technology company is looking to partner with companies from their formation through to commercialization, including expansion of operations and channel access.   The firm considers a variety of engagement models including research collaborations, licenses, investments and acquisition when partnering with companies aligned with the firm’s core businesses and new areas of strategic interest, seeking opportunities from around the globe.

Sectors and Subsectors of Interest:

The firm is currently seeking innovative companies working in sectors of Medical Technology, Diagnostics, and Healthcare IT. Within these areas, the firm is most interested in technologies including Information Enabled Devices, Healthcare Data Analytics, Parenteral Delivery, Patient and Healthcare Worker Safety, Microfluidics and Point of Care Diagnostics, Specimen Collection and Preservation, Next Generation Sequencing, and Developing World / Maternal and Newborn Health. The firm considers opportunities in these areas on a case by case basis.

Company and Management Team Requirements:

The firm  prefers to partner with experienced management teams with a track record of accomplishment including graduates from respected accelerators and incubators, providing in-kind support to advance business plan development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Venture Capital company with offices in the US and Europe is currently looking to make investments out of its fourth fund. The firm is looking to make venture stage investment generally falling in the range of $2-$6 million though investments may fall outside of this range depending upon the opportunity. The firm also reserves additional capital for follow on rounds. The firm is most interested in companies based in the US although they are also open to investing in Eastern and Northern Europe, East Asia and Australia. The firm could make as many as 5-10 investments over the next year.

The firm is primarily interested in companies developing therapeutics and to a lesser extent medical devices and research tools. Within the Therapeutics space the firm has a slight preference for companies working with platform technologies although they are open to single asset companies as well. The firm is willing to invest in small molecules, biologics, and cell and gene therapy. The firm is willing to consider opportunities from preclinical through phase III of clinical trials though most of their investments will likely be allocated to later stage companies. The firm generally only considers pre-clinical stage companies if there is a clear path to exit in a shortened timeframe. The firm is highly interested in area of RNA therapeutics, Oncology, Structural Heart and Gene Therapy and is generally less interested in CNS disorders.  For medical device companies the firms looks for technologies that are into clinical trials with a working prototype and is agnostic in terms of technology type and indication.

The firm is looking for private or publically held companies, and has special interest in companies considering going public as well as secondary’s investments. The firm prefers to invest as a member of a syndicate and does not always require a board seat following investment. The firm looks to act as a value add investor helping companies expand their networks and filling in holes in existing management.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com